Intravenous administration of iron gluconate during haemodialysis

Calvar, Cecilia; Mata, Dolores de la; Alonso, Carmen; Ramos, Barbara Resende; Novales, E. Lopez de

doi:10.1093/ndt/12.3.574

Cited by 13 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sodium ferric gluconate and iron sucrose appear to have more favorable safety profiles than iron dextran, with the largest prospective safety comparison to date revealing that sodium ferric gluconate is similar to placebo in the incidence of serious anaphylactoid reactions [40]. Adverse events associated with sodium ferric gluconate include hypotension, rash, and chest or abdominal pain, with an overall incidence of 1.3% for serious reactions [41]; among 74 serious reactions with sodium ferric gluconate reported in Europe between 1976 and 1996, none were fatal [31•]. All injectable iron compounds can cause a "free iron" reaction (nausea, hypotension, and redness of the face), which is thought to be a consequence of exceeding transferrin saturation, but these reactions are typically not life threatening [39,42].…”

Section: Role Of Iron Supplementation In Erythropoietic Therapymentioning

confidence: 99%

Management of anemia in patients with cancer

Steensma

2004

Curr Oncol Rep

View full text Add to dashboard Cite

Anemia is extremely common in patients with cancer. Low hemoglobin levels are associated with diminished quality of life and possibly decreased overall survival. Successful treatment of anemia has undeniable benefits for patients, often yielding dramatic symptomatic improvement that can be very satisfying for clinicians to observe. This review focuses on evolving issues in the management of anemia in patients suffering from cancer. Topics addressed include new evidence-based guidelines concerning the use of epoetin alfa, the evolving role of darbepoetin alfa in cancer-associated anemia, the potential for concomitant iron supplementation to maximize response to erythropoietic agents, the unresolved question of whether erythropoietin use affects survival in cancer patients, new concerns about the risk of thromboembolism in cancer patients with higher hemoglobin levels who are receiving epoetin, and possible immunosuppressive effects of blood product transfusions that may have relevance to neoplasia progression.

show abstract

Section: Role Of Iron Supplementation In Erythropoietic Therapymentioning

confidence: 99%

Management of anemia in patients with cancer

Steensma

2004

Curr Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Adverse events that have been reported associated with ferric gluconate include hypotension, rash, chest or abdominal pain, with an incidence of less than 5% 35 . Another potential adverse effect of intravenous iron therapy is a clinical syndrome of acute iron toxicity (nausea, facial reddening, and hypotension) which has been attributed to oversaturation (>100%) of transferrin.…”

Section: Current Status Of Perisurgical Erythropoietin Therapymentioning

confidence: 99%

Current Status of Perisurgical Erythropoietin [Therapy

Goodnough

2000

Transfus Alt Transfus Med

View full text Add to dashboard Cite

SUMMARY Recombinant human erythropoietin (EPO) therapy has been approved for use in patients undergoing autologous blood donation (ABD) in Japan, the European Union, and Canada since 1993,1994, and 1996 respectively, and is now approved for perisurgical adjuvant therapy in Canada, Australia, the U.S. and the European Union (Table 1)1. Emerging strategies to improve the dose‐response relationship between erythropoietin therapy and red cell production include low dose EPO and intravenous iron therapy, to be addressed in this discussion.

show abstract

“…Calvar et al. ( 50) reported minimal side effects in fewer than 5% of patients who received 125 mg of iron gluconate. These symptoms did not occur during infusion of 62.5 mg iron gluconate.…”

Section: Ferric Gluconatementioning

confidence: 99%